Sep 19, 2018 Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal DementiaBUSINESS WIRE)--Sep 19, 2018--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for ... read morePublished on 2018-09-19